What is Axoft?
Axoft operates at the intersection of biotechnology and advanced materials science, focusing on the creation of scalable, bioinspired implants. Unlike traditional neural interfaces that often face challenges with biocompatibility and signal degradation, Axoft's technology is engineered to integrate harmoniously with biological tissues. This approach aims to provide a stable, high-fidelity bridge between electronic systems and the nervous system, effectively addressing critical gaps in current neuro-prosthetic and therapeutic applications. By prioritizing long-term stability and signal integrity, the company is carving out a significant market position within the high-growth neurotechnology landscape, targeting both clinical research and future therapeutic interventions.
How much funding has Axoft raised?
Axoft has raised a total of $63M across 2 funding rounds:
Angel/Seed
$8M
Series A
$55M
Angel/Seed (2022): $8M with participation from The Engine, Amino Capital, Alumni Ventures, and Decent Capital
Series A (2026): $55M led by Gaorong Capital, Hillhouse, Charoen Pokphand Group, and Alumni Ventures
Key Investors in Axoft
Gaorong Capital
Gaorong Capital is a prominent venture capital firm established in 2014, known for its strategic focus on high-growth technology and innovation-driven sectors.
Hillhouse
Hillhouse is a global private equity firm that manages long-term capital for institutional investors, with a deep focus on healthcare, industrials, and business services.
Charoen Pokphand Group
Charoen Pokphand Group is a major multinational conglomerate that invests in sustainable development across food production, telecommunications, and diverse industrial sectors.
What's next for Axoft?
With the successful closure of this major strategic investment, Axoft is entering a critical phase of operational scaling and clinical development. The company is expected to utilize these resources to expand its research and development capabilities, refine its manufacturing processes for clinical-grade implants, and initiate rigorous human trials. As Axoft transitions from a research-focused entity to a clinical-stage enterprise, the focus will shift toward regulatory milestones and the establishment of strategic partnerships with healthcare providers. This capital infusion provides the necessary runway to navigate the complex regulatory environment of medical devices while maintaining the technical rigor required to bring its transformative neural interface solutions to the global market.
See full Axoft company page
